Implantica (IMP) Q1 2026 earnings summary

Executive summary

• Achieved FDA PMA submission for RefluxStopⓇ, positioning for U.S. launch pending approval, with strong clinical and economic evidence and unmatched long-term efficacy and safety data.

• Over 1,500 procedures performed in Europe, with 50 hospitals adopting the device and expanding reimbursement and adoption, especially in Italy and Spain.

• Johnson & Johnson's withdrawal of LINX outside the U.S. opens significant market opportunities for RefluxStopⓇ.

• U.S. manufacturing readiness and surgeon training are in place for rapid commercial rollout, with 20 surgeons trained and 10,000 devices produced.

• Pipeline and platform technologies, including eHealth and wireless energizing, offer future growth beyond RefluxStopⓇ.

Financial highlights

• Q1 2026 net sales reached EUR 857,000, up 15% year-over-year.

• Adjusted gross margin remained strong at 93%.

• Operating loss (EBIT) improved by 8% to EUR 3.9 million despite higher R&D expenses.

• Operating cash outflow reduced by 19% year-over-year to EUR 3.66 million.

• Cash and cash equivalents stood at EUR 45.5 million, with a debt-free capital structure.

Outlook and guidance

• Anticipates a much faster U.S. launch due to robust five-year clinical data, strong surgeon interest, and advanced preparations.

• Expects continued expansion in Europe, with reimbursement progress in Germany and more tender wins in Italy.

• Expansion into new indications and markets, including obesity surgery and broader GERD populations, is planned.

• Ongoing and upcoming randomized controlled trials to further validate clinical benefits and expand indications.

• Direct-to-consumer marketing planned for U.S. to accelerate adoption.